14 slides from Fresenius Se & Co. Kgaa's earnings presentation, May 3, 2001
Slide 1: Conference Call Presentation 1st quarter 2001
Fresenius Conference Call Presentation 1st quarter 2001 May 3, 2001 1/ IR/q1_2001_e
Slide 2: Fresenius Group Q1/2001: In Line with Expectations
Fresenius Group Q1/2001: In Line with Expectations Sales € 1,658 m + 21 % EBIT € 179 m +7% EAT € 62 m + 11 % 2/ IR/q1_2001_e
Slide 3: Regional Sales Growth and Distribution
Fresenius Group: Regional Sales Growth and Distribution Sales Distribution Growth by Region (%) Asia-Pacific 6% Africa 1% Europe 10 South America 5% Europe North America 24 30 % Asia-Pacific 31 South America 43 Africa 21 North America 58 % 0 10 20 30 40 50 Q1/2000: 1.7 €bn 3/ IR/q1_2001_e
Slide 4: Sales by Business Segment Q1/2001
Fresenius Group: Sales by Business Segment Q1/2001 €m Q1/2000 Q1/2001 Growth Fresenius Medical Care 1,016 1,256 + 24 % Fresenius Kabi 257 307 + 19 % Fresenius ProServe 67 60 - 10 % Fresenius HemoCare 47 52 + 11 % Inter-divisional sales - 14 - 17 Group total 1,373 1,658 + 21 % 4/ IR/q1_2001_e
Slide 5: EBIT by Business Segment Q1/2001
Fresenius Group: EBIT by Business Segment Q1/2001 €m Q1/2000 Q1/2001 Growth Fresenius Medical Care 147 170 + 16 % Fresenius Kabi 22 10 - 55 % Fresenius ProServe 2 3 + 50 % Fresenius HemoCare 1 2 + 100 % Corporate/Others -5 -6 Group total 167 179 +7% 5/ IR/q1_2001_e
Slide 6: Fresenius Kabi: Key Figures Q1/2001
Fresenius Kabi: Key Figures Q1/2001 €m Q1/2000 Q1/2001 Growth Sales 257 307 + 19 % Product Business 229 262 + 14 % Calea (Ambulatory Care) 28 45 + 61 % EBITDA 39 32 -18 % EBITDA margin 15.2% 10.4 % EBIT 22 10 - 55 % EBIT margin 8.6 % 3.3 % 6/ IR/q1_2001_e
Slide 7: Fresenius ProServe: Key Figures Q1/2001
Fresenius ProServe: Key Figures Q1/2001 €m Q1/2000 Q1/2001 Growth Sales 67 60 - 10 % Projects 40 25 - 38 % Service 27 35 + 30 % EBITDA 3 4 + 33 % EBITDA margin 4.5 % 6.7 % EBIT 2 3 + 50 % EBIT margin 3.0 % 5.0 % 7/ IR/q1_2001_e
Slide 8: ProServe: Order Entry and Orders on Hand Q1/2001
Fresenius ProServe: Order Entry and Orders on Hand Q1/2001 €m Q1/2000 Q1/2001 Growth Order entry 51 149 192 % Orders on hand (2000: 31.12.) 305 368 21 % Major contracts: • Philippines: Modernisation of 23 government hospitals • Gabun: Construction of a turn-key hospital • Austria: Planning and const
Slide 9: Fresenius HemoCare: Key Figures Q1/2001
Fresenius HemoCare: Key Figures Q1/2001 €m Q1/2000 Q1/2001 Growth Sales 47 52 + 11 % EBITDA 4 5 + 25 % EBITDA margin 8.5 % 9.6 % EBIT 1 2 + 100 % EBIT margin 2.1 % 3.8 % 9/ IR/q1_2001_e
Slide 10: Fresenius Group: Key Figures
Fresenius Group: Key Figures Q1/2000 Q1/2001 Change Sales €m 1,373 1,658 21 % EBITDA €m 255 291 14 % Depreciation €m - 88 - 112 27 % EBIT €m 167 179 7% Interest result €m - 62 - 66 6% EBT €m 105 113 8% Taxes €m - 49 - 51 4% Tax rate % 46.7 45.1 Net income €m 56 62 11 % Net income after minority inte
Slide 11: Capital Expenditure and Cash Flow
Fresenius Group: Capital Expenditure and Cash Flow €m Capex Cash flow 450 402 400 Tangible/ Q1/2001: intangible assets 350 Acquisitions Capex 300 € 488 m + 328 % 250 Cash flow 200 182 € 182 m + 23 % 148 150 123 100 86 62 47 52 50 26 0 Q1/1999 Q1/2000 Q1/2001 Q1/1999 Q1/2000 Q1/2001 11 / IR/q1_2001_e
Slide 12: Cash Flow Statement
Fresenius Group: Cash Flow Statement €m Q1/2000 Q1/2001 Change Cash flow 148 182 + 23 % Change in working capital -46 -130 + 183 % Operating cash flow 102 52 - 49 % Regular capex (net) - 58 - 83 + 43 % Free cash flow (before acquisitions and dividends) 44 - 31 - 170 % 12 / IR/q1_2001_e
Slide 13: Solid Balance Sheet Structure
Fresenius Group: Solid Balance Sheet Structure Assets Equity + Liabilities 31.12.2000 31.3.2001 31.12.2000 31.3.2001 Fixed assets Equity 43 % 42 % 62 % 62 % Debt 29% 32% Current assets 9% 8% Inventories Other Other liabilities current assets 29 % 30 % 28% 26% Balance sheet total 6,473 7,130 6,473 7,
Slide 14: Forward-looking statements
Fresenius This presentation includes certain forward-looking statements. Actual results could differ materially from those included in the forward-looking statements due to various risk factors and uncertainties, including changes in business, economic and competitive conditions, regulatory reforms,